Oct 8 (Reuters) - IMV Inc IMV.TO :
* IMV PROVIDES UPDATES ON COVID-19 VACCINE PROGRAM
* IMV INC - CLINICAL PLAN UPDATED TO RUN A LARGER PHASE 1/2 STUDY WITH GOAL TO EXPEDITE LATER-STAGE DEVELOPMENT
* IMV - SELECTED FOR ADDITIONAL FUNDING BY CANADIAN GOVERNMENT BRINGING TOTAL SUPPORT TO $10M FOR CLINICAL DEVELOPMENT AND MANUFACTURING OF DPX-COVID-19
* IMV INC - COLLABORATION INITIATED WITH A GLOBAL MANUFACTURING PARTNER TO DEVELOP AND EXPAND MANUFACTURING CAPACITY UP TO SEVERAL HUNDRED MILLION OF DOSES
* IMV INC - PHASE 1/2 TRIAL IS EXPECTED TO BE INITIATED BEFORE END OF 2020
* IMV INC - TOTAL DPX-COVID19 FUNDING SECURED BY CO FROM DIFFERENT GOVERNMENTAL SOURCES TO DATE IS ABOUT $10 MILLION
* IMV INC - IN CONSULTATION WITH HEALTH CANADA, DECIDED TO COMBINE ITS ORIGINAL PHASE 1 AND 2 STUDIES INTO A SINGLE TRIAL
* IMV INC - CONTINUES EFFORTS TO SECURE ADDITIONAL NON-DILUTIVE FUNDING, AGREEMENTS WITH COMMERCIAL PARTNERS TO CONDUCT ITS CLINICAL TRIALS
* IMV INC - COLLABORATION HAS POTENTIAL TO BRING TWO ADDITIONAL PRODUCTION SITES IN INDIA AND EUROPE